2024-11-13T13:41:30-06:00 2023-12-31 341322309 CIUNI & PANICHI INC 25201 CHAGRIN BLVD 200 CLEVELAND OH 441225683 990 2023-01-01 852221062 ALK POSITIVE INC ALKP 6785769913 6595 ROSWELL RD G2310 ATLANTA GA 30238 KIRK SMITH PRESIDENT 6785769913 2024-11-12 1 1 MICHAEL B KLEIN CPA P00359504 2168317171 2024-11-12 2023 2024-10-15 13:58:12Z KIRK SMITH 6595 ROSWELL RD G2310 ATLANTA GA 30238 2639895 0 X WWW.ALKPOSITIVE.ORG X 2020 DE WE ARE A PATIENT-DRIVEN ORGANIZATION SEEKING A CURE AND WORKING TO (CONTINUED ON SCHEDULE O)IMPROVE PATIENTS' QUALITY OF LIFE AND LIFE EXPECTANCY WORLDWIDE. 12 12 4 56 0 0 1596649 2533927 0 18525 5542 53353 0 2858 1602191 2608663 0 2388548 0 0 76731 463962 0 0 38224 465010 541599 541741 3394109 1060450 -785446 4507425 4700238 33184 1011443 4474241 3688795 X WE ARE A PATIENT-DRIVEN ORGANIZATION SEEKING A CURE AND WORKING TO IMPROVE PATIENTS' QUALITY OF LIFE AND LIFE EXPECTANCY WORLDWIDE. 0 0 3211670 2388548 21383 ALK POSITIVE, INC. IS A PATIENT DRIVEN 501(C)(3) NONPROFIT CORPORATION PROVIDING SUPPORT, EMPATHY, AND RESEARCH FUNDING TO CHANGE THE FUTURE FOR ALK-POSITIVE CANCER PATIENTS. ALK-POSITIVE CANCER IS ESTIMATED TO OCCUR IN APPROXIMATELY 100,000 PATIENTS WORLDWIDE EVERY YEAR. ALTHOUGH THE VAST MAJORITY OF CASES OCCUR AS LUNG CANCER, IT CAN ALSO ORIGINATE IN MANY OTHER ORGANS. THE MEDIAN AGE FOR ALK-POSITIVE PATIENTS AT DIAGNOSIS IS ABOUT 50 YEARS WITH MANY IN THEIR FORTIES, THIRTIES AND EVEN YOUNGER. APPROXIMATELY 55% OF ALK-POSITIVE PATIENTS ARE FEMALE AND THE DISEASE OCCURS WITH PEOPLE OF ALL RACES.(CONTINUED ON SCHEDULE O)IN 2017, SOME ALK-POSITIVE CANCER PATIENTS AND CAREGIVERS FORMED THE OUTREACH MANAGEMENT GROUP TO PARTNER WITH THE LUNGEVITY FOUNDATION IN ORDER TO RAISE FUNDS FOR CANCER RESEARCH. IN 2018, THE PARTNERSHIP WAS FORMALIZED INTO A JOINT FUNDRAISING AND RESEARCH AGREEMENT WITH BOTH LUNGEVITY AND THE GO2 FOUNDATION FOR LUNG CANCER. FROM 2017 TO 2021, THE PARTNERSHIPS GENERATED OVER $4.7M IN CONTRIBUTIONS AND AWAREDED $2.8M IN TRANSLATIONAL RESEARCH GRANTS WITH THE PURPOSE OF IMPROVING ALK-POSITIVE CANCER PATIENT OUTCOMES. BY MARCH 2021, THE OUTREACH MANAGEMENT GROUP HAD INCORPORATED AND WAS RECOGNIZED BY THE IRS AS A 501(C)(3) NON PROFIT ORGANIZATION CALLED ALK POSITIVE INC. DURING 2021-22 ANOTHER $3.4M IN CONTRIBUTIONS WAS GENEROUSLY RAISED WITH RESEARCH GRANTS TOTALING $2.6M AWARDED. ALSO IN 2022, THE FIRST TWO EMPLOYEES WERE HIRED - A DIRECTOR OF RESEARCH AND CLINICAL AFFAIRS AND AN EXECUTIVE DIRECTOR.BY FAR, THE MOST EFFECTIVE TREATMENTS FOR ALK-POSITIVE CANCER ARE THE ROAL ALK TYROSINE KINASE INHIBITORS (TKI'S). THESE ARE NOW FDA APPROVED IN 1ST, 2ND AND 3RD GENERATION VERSIONS, EACH GENERATION MORE EFFECTIVE THAN THE PREVIOUS. HOWEVER, WHILE TKI'S HAVE IMPROVED MEDIAN OVERALL SURVIVAL FROM A FEW MONTHS TO MANY YEARS, ALK-POSITIVE CANCERS INEVITABLY MUTATE AND BECOME RESISTANT TO ALL TKI'S. THE ORGANIZATION CREATED THE RESEARCH REVIEW PANEL (COMMITTEE) COMPRISING VOLUNTEER ALK-POSITIVE CANCER PATIENTS, CAREGIVERS AND WORLD-RENOWNED SCIENTIFIC AND RESEARCH EXPERTS TO HELP REVIEW AND AWARD THE MOST PROMISING ALK-POSITIVE CANCER RESEARCH PROJECTS TO IMPROVE PATIENT OUTCOMES. IN 2022, THIS RESERACH TEAM WAS EXPANDED TO:-RESEARCH ACCELERATION COMMITTEE: ACCELERATE ACADEMIC AND BIOTECH RESEARCH THAT LEADS TO NEW THERAPIES FOR ALK-POSITIVE PATIENTS, INCLUDING IMMUNOTHERAPIES AND COMBINATION THERAPIES, AND NEW CLINICAL TRIALS, VIA COLLABORATION WITH ACADEMIA, INDUSTRY AND VENTURE CAPITAL.-CLINICAL TRIALS COMMITTEE: COLLABORATE WITH ACADEMIA AND INDUSTRY TO DEVELOP NEW FRAMEWORKS FOR CLINICAL TRIALS AND TO ACCELERATE CREATION, EFFECTIVE ENROLLMENT AND SUCCESSFUL READOUTS FOR CLINICAL TRIALS INVOLVING AND BENEFICIAL TO ALK-POSITIVE PATIENTS.-TRANSLATIONAL INVESTIGATIONS GROUP: FRAM AND IMPLEMENT AN INTERNAL ALK-POSITIVE RESEARCH PROGRAM THAT ADDRESSES KEY QUESTIONS FOR WHICH ANSWERS WILL ENABLE THE DEVELOPMENT OF NEW ALK THERAPIES, NIOMARKS OF TREATMENT RESPONSE AND ACCELERATED CLINICAL TRIALS. 3211670 1 1 0 0 0 0 0 0 0 0 0 0 0 1 0 0 1 0 0 0 0 0 0 0 0 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 4 0 1 4 1 0 0 0 0 0 0 0 0 0 0 0 0 X 12 12 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 0 0 X THE ORGANIZATION 6785769913 6595 ROSWELL RD G2310 ATLANTA GA 30238 KEN CULVER DIRECTOR 40.00 X 188665 0 5335 LONNA SMITH DIRECTOR 40.00 X 147875 0 3087 YVONNE DIAZ DIRECTOR 5.00 X 0 0 0 SUMMER FARMEN DIRECTOR 5.00 X 0 0 0 JT HEDGES DIRECTOR 5.00 X 0 0 0 MARC MUSCOVITCH DIRECTOR 5.00 X 0 0 0 DUNCAN PREECE DIRECTOR 5.00 X 0 0 0 NANCEE PRONSATI VICE PRESIDENT 5.00 X X 0 0 0 PATTY SACCIENTE DIRECTOR 5.00 X 0 0 0 KIRK SMITH PRESIDENT 5.00 X X 0 0 0 JEFF STURN DIRECTOR 5.00 X 0 0 0 CHRISTINA WEBER SECRETARY 5.00 X X 0 0 0 GREG WEHN DIRECTOR 5.00 X 0 0 0 TERESA WIANT DIRECTOR 5.00 X 0 0 0 336540 0 8422 2 1 1 0 0 2533927 2533927 SUMMITT TICKETS 900099 18525 18525 18525 50378 50378 34207 31232 2975 2975 2975 MISCELLANEOUS INCOME 900099 2858 2858 2858 2608663 21383 0 53353 2388548 2388548 336540 277496 40837 18207 69752 57516 8464 3772 8422 6944 1022 456 4263 3515 517 231 44985 37092 5459 2434 31995 31995 44146 30169 4257 9720 51701 33044 17384 1273 26313 21401 3744 1168 54126 53456 459 211 42614 41607 979 28 7102 3755 3150 197 PROGRAM SUPPLIES 231966 231966 BANK FEES 18961 2 18959 SECOND OPINION PROGRAM 7965 7965 LICENSES AND FEES 7584 6067 1137 380 17126 11127 5852 147 3394109 3211670 144215 38224 3675960 1431087 279114 2721557 152656 146463 16610 2327 957 26224 378816 24893 3312 3312 0 344375 4507425 4700238 33184 136443 875000 33184 1011443 X 1527106 2463997 2947135 1224798 4474241 3688795 4507425 4700238 -785446 0 X 0 1 X 1 0 X 1793039 1596649 2533927 5923615 1793039 1596649 2533927 5923615 458170 5465445 1429 50378 51807 2858 2858 5978280 20462 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 0 CONSTRUCTION IN PROGRESS - WEBSITE 44375 ADVANCE PAYMENT ON CONDITIONAL GRANT 300000 344375 2608663 0 2608663 0 2608663 3394109 0 3394109 0 3394109 0 LUNGEVITY FOUNDATION INC 228 S WABASH AVE STE 700 CHICAGO IL 60604 364433410 875000 0 RESEARCH AGREEMENT LUNG CANCER RESEARCH FOUNDATION 501 7TH AVENUE STE 230 NEW YORK NY 10018 141935776 400000 0 RESEARCH AGREEMENT 2 1 0 0 0 0 0 0 0 0 KEN CULVER DIRECTOR 188665 0 0 0 0 0 5335 0 0 0 194000 0 0 0 LONNA SMITH DIRECTOR 147875 0 0 0 0 0 3087 0 0 0 150962 0 0 0 PART I, LINE 4A THE COMPANY WILL PAY LONNA SMITH A PAYMENT OF 8 WEEKS OF CURRENT SALARY. FOR A PERIOD OF 1 YEAR FOLLOWING THE TERMINATION DATE, EMPLOYEE AGREES TO FULLY AND REASONABLY COOPERATE WITH THE COMPANY WITH RESPECT TO BUSINESS ISSUES, CLAIMS, ADMINISTRATIVE CHARGES, GOVERNMENTAL INVESTIGATIONS AND LITIGATION RELATED TO THE COMPANY OR ITS BUSINESS INTERESTS. FORM 990, PART VI, SECTION B, LINE 11B THE BOARD WILL REVIEW THE FORM 990 PRIOR TO FILING WITH THE IRS. FORM 990, PART VI, SECTION B, LINE 12C BOARD MEMBERS SIGN A COPY OF THE CONFLICT OF INTEREST FORM ANNUALLY. FORM 990, PART VI, SECTION B, LINE 15A COMPENSATION FOR THE EXECUTIVE DIRECTOR WAS BASED ON RESEARCH ONLINE, COMMITTEE AND BOARD DISCUSSIONS, AND DISCUSSIONS WITH THE EXECUTIVE RECRUITING COMPANY. FORM 990, PART VI, SECTION C, LINE 19 GOVERNING AND FINANCIAL DOCUMENTS ARE AVAILABLE UPON REQUEST.